nodes	percent_of_prediction	percent_of_DWPC	metapath
Bumetanide—CA9—cervical cancer	0.85	1	CbGaD
Bumetanide—CFTR—semen—cervical cancer	0.0147	0.14	CbGeAlD
Bumetanide—CFTR—exocrine gland—cervical cancer	0.00623	0.0592	CbGeAlD
Bumetanide—CA14—Reversible hydration of carbon dioxide—CA9—cervical cancer	0.00619	0.164	CbGpPWpGaD
Bumetanide—CA5A—Reversible hydration of carbon dioxide—CA9—cervical cancer	0.00603	0.16	CbGpPWpGaD
Bumetanide—CA5B—Reversible hydration of carbon dioxide—CA9—cervical cancer	0.00563	0.149	CbGpPWpGaD
Bumetanide—CA7—Reversible hydration of carbon dioxide—CA9—cervical cancer	0.00563	0.149	CbGpPWpGaD
Bumetanide—SLC12A2—exocrine gland—cervical cancer	0.00547	0.052	CbGeAlD
Bumetanide—CA12—Reversible hydration of carbon dioxide—CA9—cervical cancer	0.00522	0.138	CbGpPWpGaD
Bumetanide—CA4—Reversible hydration of carbon dioxide—CA9—cervical cancer	0.00416	0.11	CbGpPWpGaD
Bumetanide—Furosemide—CA9—cervical cancer	0.00367	0.537	CrCbGaD
Bumetanide—SLC12A4—uterine cervix—cervical cancer	0.00342	0.0325	CbGeAlD
Bumetanide—Indapamide—CA9—cervical cancer	0.00316	0.463	CrCbGaD
Bumetanide—SLC12A4—mammalian vulva—cervical cancer	0.00299	0.0284	CbGeAlD
Bumetanide—CA5A—female reproductive system—cervical cancer	0.00298	0.0283	CbGeAlD
Bumetanide—SLC12A4—uterus—cervical cancer	0.00285	0.0271	CbGeAlD
Bumetanide—CFTR—epithelium—cervical cancer	0.00271	0.0257	CbGeAlD
Bumetanide—SLC12A4—female reproductive system—cervical cancer	0.00256	0.0243	CbGeAlD
Bumetanide—CFTR—renal system—cervical cancer	0.00251	0.0239	CbGeAlD
Bumetanide—CA7—renal system—cervical cancer	0.00248	0.0235	CbGeAlD
Bumetanide—SLC12A2—epithelium—cervical cancer	0.00238	0.0226	CbGeAlD
Bumetanide—SLC12A4—female gonad—cervical cancer	0.00233	0.0221	CbGeAlD
Bumetanide—SLC12A2—decidua—cervical cancer	0.00225	0.0214	CbGeAlD
Bumetanide—SLC12A2—renal system—cervical cancer	0.00221	0.021	CbGeAlD
Bumetanide—SLC12A2—endometrium—cervical cancer	0.00214	0.0203	CbGeAlD
Bumetanide—SLC10A1—renal system—cervical cancer	0.00209	0.0198	CbGeAlD
Bumetanide—SLC12A2—mammalian vulva—cervical cancer	0.00207	0.0196	CbGeAlD
Bumetanide—CFTR—female reproductive system—cervical cancer	0.00201	0.0191	CbGeAlD
Bumetanide—SLC12A1—epithelium—cervical cancer	0.002	0.019	CbGeAlD
Bumetanide—SLC22A11—renal system—cervical cancer	0.00191	0.0181	CbGeAlD
Bumetanide—SLC22A7—renal system—cervical cancer	0.00186	0.0177	CbGeAlD
Bumetanide—SLC12A1—renal system—cervical cancer	0.00185	0.0176	CbGeAlD
Bumetanide—CFTR—female gonad—cervical cancer	0.00183	0.0174	CbGeAlD
Bumetanide—SLC12A2—female reproductive system—cervical cancer	0.00177	0.0168	CbGeAlD
Bumetanide—CA9—female reproductive system—cervical cancer	0.00174	0.0165	CbGeAlD
Bumetanide—SLC10A1—female reproductive system—cervical cancer	0.00167	0.0159	CbGeAlD
Bumetanide—SLC12A2—female gonad—cervical cancer	0.00161	0.0153	CbGeAlD
Bumetanide—CA12—renal system—cervical cancer	0.00161	0.0153	CbGeAlD
Bumetanide—SLC12A2—vagina—cervical cancer	0.0016	0.0152	CbGeAlD
Bumetanide—SLC22A11—female reproductive system—cervical cancer	0.00153	0.0145	CbGeAlD
Bumetanide—SLC12A4—lymph node—cervical cancer	0.0015	0.0142	CbGeAlD
Bumetanide—CA5B—mammalian vulva—cervical cancer	0.00135	0.0128	CbGeAlD
Bumetanide—CA12—female reproductive system—cervical cancer	0.00129	0.0122	CbGeAlD
Bumetanide—CA5B—female reproductive system—cervical cancer	0.00116	0.011	CbGeAlD
Bumetanide—SLCO1A2—renal system—cervical cancer	0.00113	0.0107	CbGeAlD
Bumetanide—SLC22A8—renal system—cervical cancer	0.00108	0.0102	CbGeAlD
Bumetanide—CA5B—vagina—cervical cancer	0.00105	0.00992	CbGeAlD
Bumetanide—SLC12A2—lymph node—cervical cancer	0.00103	0.00982	CbGeAlD
Bumetanide—CA4—renal system—cervical cancer	0.000996	0.00946	CbGeAlD
Bumetanide—CA4—female reproductive system—cervical cancer	0.000798	0.00757	CbGeAlD
Bumetanide—SLC22A7—Fluoropyrimidine Activity—SMUG1—cervical cancer	0.000742	0.0197	CbGpPWpGaD
Bumetanide—CA4—female gonad—cervical cancer	0.000726	0.00689	CbGeAlD
Bumetanide—CA5B—lymph node—cervical cancer	0.000676	0.00642	CbGeAlD
Bumetanide—PTGS2—epithelium—cervical cancer	0.000658	0.00624	CbGeAlD
Bumetanide—PTGS2—uterine cervix—cervical cancer	0.000652	0.00619	CbGeAlD
Bumetanide—PTGS2—renal system—cervical cancer	0.00061	0.00579	CbGeAlD
Bumetanide—PTGS2—endometrium—cervical cancer	0.00059	0.0056	CbGeAlD
Bumetanide—PTGS2—uterus—cervical cancer	0.000543	0.00516	CbGeAlD
Bumetanide—SLC22A7—Fluoropyrimidine Activity—MTHFR—cervical cancer	0.000519	0.0138	CbGpPWpGaD
Bumetanide—PTGS2—female reproductive system—cervical cancer	0.000488	0.00464	CbGeAlD
Bumetanide—CA4—lymph node—cervical cancer	0.000467	0.00443	CbGeAlD
Bumetanide—PTGS2—female gonad—cervical cancer	0.000444	0.00422	CbGeAlD
Bumetanide—PTGS2—C-MYB transcription factor network—PIAS3—cervical cancer	0.000442	0.0117	CbGpPWpGaD
Bumetanide—PTGS2—vagina—cervical cancer	0.000442	0.00419	CbGeAlD
Bumetanide—CA9—HIF-1-alpha transcription factor network—TERT—cervical cancer	0.000348	0.00922	CbGpPWpGaD
Bumetanide—PTGS2—lymph node—cervical cancer	0.000286	0.00271	CbGeAlD
Bumetanide—SLC22A7—Fluoropyrimidine Activity—TP53—cervical cancer	0.000197	0.00523	CbGpPWpGaD
Bumetanide—PTGS2—C-MYB transcription factor network—HES1—cervical cancer	0.000126	0.00335	CbGpPWpGaD
Bumetanide—CA14—Metabolism—CA9—cervical cancer	0.000126	0.00334	CbGpPWpGaD
Bumetanide—CA5A—Metabolism—CA9—cervical cancer	0.000123	0.00325	CbGpPWpGaD
Bumetanide—PTGS2—Integrated Pancreatic Cancer Pathway—RARB—cervical cancer	0.00012	0.00319	CbGpPWpGaD
Bumetanide—CA7—Metabolism—CA9—cervical cancer	0.000114	0.00303	CbGpPWpGaD
Bumetanide—CA5B—Metabolism—CA9—cervical cancer	0.000114	0.00303	CbGpPWpGaD
Bumetanide—PTGS2—Defective AMN causes hereditary megaloblastic anemia 1—MTHFR—cervical cancer	0.000108	0.00286	CbGpPWpGaD
Bumetanide—PTGS2—Selenium Micronutrient Network—MTHFR—cervical cancer	0.000107	0.00283	CbGpPWpGaD
Bumetanide—CA12—Metabolism—CA9—cervical cancer	0.000106	0.00281	CbGpPWpGaD
Bumetanide—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CASP3—cervical cancer	9.94e-05	0.00264	CbGpPWpGaD
Bumetanide—SLC10A1—Metabolism—CA9—cervical cancer	8.86e-05	0.00235	CbGpPWpGaD
Bumetanide—PTGS2—Signaling mediated by p38-alpha and p38-beta—TP53—cervical cancer	8.48e-05	0.00225	CbGpPWpGaD
Bumetanide—CA4—Metabolism—CA9—cervical cancer	8.45e-05	0.00224	CbGpPWpGaD
Bumetanide—PTGS2—Aryl Hydrocarbon Receptor—EGFR—cervical cancer	8.11e-05	0.00215	CbGpPWpGaD
Bumetanide—CA9—Cellular responses to stress—MTOR—cervical cancer	7.41e-05	0.00196	CbGpPWpGaD
Bumetanide—PTGS2—C-MYB transcription factor network—CD4—cervical cancer	7.12e-05	0.00189	CbGpPWpGaD
Bumetanide—CA9—Cellular responses to stress—STAT3—cervical cancer	5.72e-05	0.00152	CbGpPWpGaD
Bumetanide—CA14—Metabolism—MTHFR—cervical cancer	5.1e-05	0.00135	CbGpPWpGaD
Bumetanide—PTGS2—Spinal Cord Injury—CASP3—cervical cancer	5e-05	0.00133	CbGpPWpGaD
Bumetanide—CA5A—Metabolism—MTHFR—cervical cancer	4.97e-05	0.00132	CbGpPWpGaD
Bumetanide—CA5B—Metabolism—MTHFR—cervical cancer	4.64e-05	0.00123	CbGpPWpGaD
Bumetanide—CA7—Metabolism—MTHFR—cervical cancer	4.64e-05	0.00123	CbGpPWpGaD
Bumetanide—PTGS2—Integrated Pancreatic Cancer Pathway—CASP8—cervical cancer	4.49e-05	0.00119	CbGpPWpGaD
Bumetanide—CA9—Cellular responses to stress—TP53—cervical cancer	4.37e-05	0.00116	CbGpPWpGaD
Bumetanide—SLCO1A2—Metabolism—CA9—cervical cancer	4.36e-05	0.00116	CbGpPWpGaD
Bumetanide—CA12—Metabolism—MTHFR—cervical cancer	4.3e-05	0.00114	CbGpPWpGaD
Bumetanide—PTGS2—Spinal Cord Injury—EGFR—cervical cancer	3.82e-05	0.00101	CbGpPWpGaD
Bumetanide—SLC10A1—Metabolism—MTHFR—cervical cancer	3.59e-05	0.000954	CbGpPWpGaD
Bumetanide—CA4—Metabolism—MTHFR—cervical cancer	3.43e-05	0.00091	CbGpPWpGaD
Bumetanide—PTGS2—Integrated Pancreatic Cancer Pathway—CASP3—cervical cancer	3.4e-05	0.000902	CbGpPWpGaD
Bumetanide—PTGS2—Disease—WNT2—cervical cancer	3.33e-05	0.000883	CbGpPWpGaD
Bumetanide—PTGS2—Integrated Pancreatic Cancer Pathway—CTNNB1—cervical cancer	3.28e-05	0.00087	CbGpPWpGaD
Bumetanide—PTGS2—Spinal Cord Injury—TP53—cervical cancer	3.21e-05	0.00085	CbGpPWpGaD
Bumetanide—CA9—Metabolism—MTHFR—cervical cancer	2.77e-05	0.000735	CbGpPWpGaD
Bumetanide—PTGS2—Metabolism—CA9—cervical cancer	2.63e-05	0.000698	CbGpPWpGaD
Bumetanide—PTGS2—Integrated Pancreatic Cancer Pathway—EGFR—cervical cancer	2.6e-05	0.000689	CbGpPWpGaD
Bumetanide—PTGS2—Disease—WNT5A—cervical cancer	2.52e-05	0.000669	CbGpPWpGaD
Bumetanide—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—cervical cancer	2.18e-05	0.000578	CbGpPWpGaD
Bumetanide—SLCO1A2—Metabolism—MTHFR—cervical cancer	1.77e-05	0.000469	CbGpPWpGaD
Bumetanide—PTGS2—Disease—HES1—cervical cancer	1.45e-05	0.000385	CbGpPWpGaD
Bumetanide—PTGS2—Disease—MTHFR—cervical cancer	1.28e-05	0.000338	CbGpPWpGaD
Bumetanide—PTGS2—Disease—TERT—cervical cancer	1.27e-05	0.000337	CbGpPWpGaD
Bumetanide—PTGS2—Disease—FGFR3—cervical cancer	1.17e-05	0.00031	CbGpPWpGaD
Bumetanide—PTGS2—Disease—NOTCH1—cervical cancer	1.1e-05	0.000291	CbGpPWpGaD
Bumetanide—PTGS2—Metabolism—MTHFR—cervical cancer	1.07e-05	0.000283	CbGpPWpGaD
Bumetanide—PTGS2—Disease—MTOR—cervical cancer	8.21e-06	0.000218	CbGpPWpGaD
Bumetanide—PTGS2—Disease—CD4—cervical cancer	8.2e-06	0.000217	CbGpPWpGaD
Bumetanide—PTGS2—Disease—CTNNB1—cervical cancer	7.28e-06	0.000193	CbGpPWpGaD
Bumetanide—PTGS2—Disease—STAT3—cervical cancer	6.35e-06	0.000168	CbGpPWpGaD
Bumetanide—PTGS2—Disease—EGFR—cervical cancer	5.77e-06	0.000153	CbGpPWpGaD
